Visual and Refractive Outcomes of The ClarVista HARMONI™ Modular Intraocular Lens System (HMIOL)
NCT ID: NCT03681886
Last Updated: 2021-01-05
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
150 participants
INTERVENTIONAL
2016-01-09
2017-12-14
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Clinical Investigation of the ClarVista HARMONI™ Modular Intraocular Lens Implant Following Cataract Surgery
NCT02521766
Evaluation of the Safety and Performance of the HARMONI® Toric Lens
NCT03050697
ClarVista HARMONI Toric Trial With Intraoperative Exchange
NCT03054649
Clinical Investigation of the AcrySof IQ Vivity Extended Vision Intraocular Lens (IOL)
NCT04098367
Clinical Outcomes of Clareon Vivity Intraocular Lens With Mini-Monovision Approach
NCT05821101
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Alcon Research, LLC, acquired ClarVista Medical in 2017. This study was designed and conducted by ClarVista Medical, Inc. The study results were collected, analyzed, and provided by ClarVista Medical, Inc. to Alcon Research, LLC.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Primary Implantation (Cohort 1)
Primary implantation with HMIOL through Month 1 visit, followed by study exit. 1 site followed up to Month 12.
Harmoni Modular Intraocular Lens
Two-component system consisting of a base and a separate optic that allows for an intraoperative exchange of the optic only without direct manipulation of the capsular bag.
Optic Exchange (Cohort 2)
Subset of Cohort 1 with optic exchange at Month 1 post primary implantation, followed up to Month 1 post optic exchange
Harmoni Modular Intraocular Lens
Two-component system consisting of a base and a separate optic that allows for an intraoperative exchange of the optic only without direct manipulation of the capsular bag.
Optic Exchange
Removal of one optic and replacement with another for the purpose of improving refractive outcomes
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Harmoni Modular Intraocular Lens
Two-component system consisting of a base and a separate optic that allows for an intraoperative exchange of the optic only without direct manipulation of the capsular bag.
Optic Exchange
Removal of one optic and replacement with another for the purpose of improving refractive outcomes
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Willing and able to return for scheduled treatment and follow-up examinations;
* Planned removal of cataracts (cortical, nuclear, subcapsular, or a combination) by manual phacoemulsification cataract extraction;
Exclusion Criteria
* Traumatic or congenital cataract;
* Pregnancy or planned pregnancy during the study period;
* Medications that may confound the outcome or increase risk to the subject;
* Any clinical finding or intraocular complication during primary cataract surgery or Implantation of the lens system likely to increase complications or risk to the subject;
22 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
ClarVista Medical
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sr. Clinical Trial Lead, CDMA Surgical
Role: STUDY_DIRECTOR
Alcon Research, LLC
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Statistical Analysis Plan
Document Type: Study Protocol
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CVM-00001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.